Mirion Technologies, Inc.

MIR · Healthcare · FY2025 filings · · Shallow moat ·

Doesn't clear the bar

Shallow moat
Share / Embed this score
Embed this score

The five investor questions

80

2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $612M to $925M, increasing; diluted EPS -0.86 to 0.11, increasing.

71

Median gross margin 43.2% over 7y, very stable.

0

Median ROIC 0.1%, above the 12% hurdle in 0% of years.

53

Net debt/EBITDA 0.2x, interest coverage 1x.

44

Owner earnings changed trend unclear over up to the ten most recent annual observations.

Price vs. value if growth stopped today

A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.

Above value if growth stopped todayBelow value if growth stopped today
No price data
$28.8M
Unavailable — insufficient owner-earnings data
Unavailable — insufficient growth-model data
$16.69
No price data

This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.

Among the current top-score group, the median current price is 238% above the zero-growth estimate across 49 of the current top 50 companies by Moat Score with both values.

Score records captured Sep 4, 2026.

Exactly which 50 companies?

FTNT, META, MEDP, IBEX, MSFT, GOOG, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, RMD, GRMN, PCTY, EAT, UI, SSD, MNST, DOCS, LRCX, MCO, CPRT, NTAP, NVDA, CORT, SFM, MPTI, ULTA, SN, ROL, CTAS, PAYC, IRMD, INTU, DECK, MORN, JKHY, TPR, LGCY, DAL, GWW, ISRG, MPWR, LOPE

Missing a usable price or zero-growth estimate: ANF.

Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

9 years of fundamentals

The business, in plain English

Mirion Technologies, Inc. booked $925M of revenue in FY2025 in the Healthcare sector and kept 47.4% of it as gross profit — a solid-margin business by that measure. After every other cost, 3.1% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $440M (FY2019) to $925M (FY2025) — about 13.2% a year compounded over 6 years.

It earned 2.5% on invested capital in the latest filed year, FY2025. Across the full 4-year measurable filed record, median ROIC was 0.1%. Over the v3 recent window (4 measurable filed years), median ROIC was 0.1%. The Returns on Capital filter above scores it 0/100.

The balance sheet carried $445M of total debt in FY2025 against $131M of owner earnings — roughly 3.4 years of owner earnings to retire it all. Balance-Sheet Safety scores it 53/100.

Put together: Business Trend is the strongest of the five filters (80/100) and Returns on Capital the weakest (0/100), which is how MIR lands at 50/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2017–FY2025 · 9 fiscal years, normalized from MIR’s SEC filings

Sales, as filed$925M FY2025
$0$500M2017202020232025
Revenue kept after cost of goods47.4% FY2025
0%20%40%2017202020232025
Standard ROIC or separately labeled Operating ROICStandard ROIC 2.4% FY2025

Exact FY and FY-1 financing invested-capital inputs are required.. Exact FY and FY-1 Operating Invested Capital inputs are required.

−20%0%2017202020232025
Cash an owner could take out$131M FY2025
$02017202020232025

The explained ROIC gaps have filed inputs but no meaningful positive invested-capital denominator. Other gaps mean the item is not in the filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Visual explainers

The filing-backed explainer service is temporarily unavailable, so no partial or guessed chart is shown.

Moat Score history

17 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale49.5 / 100
0406080100WideNarrowShallowNo moatJul 17, 2026Sep 4, 2026

Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

  1. Normalizer upgraded unstamped (version unknown)tomoat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
  2. Methodology upgraded moat-index@2.0.0tomoat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
  3. Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

The insider-filing service is temporarily unavailable, so no partial or guessed answer is shown for MIR.

Healthcare context

#188 of 708 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #186SHC SOTERA HEALTH COMPANY49.8 out of 100, Shallow moatShallow moat
  2. #187GEHC GE HEALTHCARE TECHNOLOGIES INC.49.7 out of 100, Shallow moatShallow moat
  3. #189KEQU Kewaunee Scientific Corporation49.4 out of 100, Shallow moatShallow moat
  4. #190BBIO BridgeBio Pharma, Inc.49.4 out of 100, Shallow moatShallow moat

Compare MIR with its nearest peersAll Healthcare companies on the Index →

Common questions about MIR

Does Mirion Technologies, Inc. have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores Mirion Technologies, Inc. (MIR) 49.5 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 80, pricing power 71, returns on capital 0, balance-sheet safety 53, capital allocation 44.
How has MIR's Moat Score changed over time?
The record logs 17 readings since Jul 17, 2026; the latest reads 49.5 out of 100 (shallow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.